DBT and Escitalopram in Borderline Personality Disorder - Tabular View

Tracking Information

First Received Date ^ICMJE

November 17, 2005

Last Updated Date

November 17, 2005

Start Date ^ICMJE

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Measures of impulsivity, aggression, affective impulsivity, immediate and delayed memory, and cognitive processing at baseline, 6 months and 9 months

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

No Changes Posted

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

DBT and Escitalopram in Borderline Personality Disorder

Official Title ^ICMJE

Effects of Dialectical Behavioral Therapy and Escitalopram on Impulsive Aggression, Affective Instability and Cognitive Processing in Borderline Personality Disorder

Brief Summary

Subjects will receive six months of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist. Half the subjects will concurrently receive escitalopram while half will receive placebo, in a randomized double-blind design.

Detailed Description

Study Phase

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment

Condition ^ICMJE

Borderline Personality Disorder

Intervention ^ICMJE

Behavioral: Dialectical Behavioral Therapy
Drug: Escitalopram

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria: Is a male or female between 18 and 60 who meets criteria for Borderline Personality Disorder and has been off psychotropic medications for at least 2 weeks (6 weeks for fluoxetine).

Exclusion Criteria: Meets criteria for Schizophrenia, Bipolar Disorder, Mental Retardation, current or recent Substance Dependence or a current Major Depressive Episode. Subjects also should not currently be in individual psychotherapy. (Case management and work therapy programs are allowed.)

Gender

Both

Ages

18 Years to 60 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact: Emily Hart

212-241-0441

mpgroup@mssm.edu

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00255554

Responsible Party

Study ID Numbers ^ICMJE

3277-03-0027

Study Sponsor ^ICMJE

Bronx VA Medical Center

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

Marianne Goodman, MD

Bronx VA Medical Center/Mount Sinai School of Medicine

Information Provided By

Bronx VA Medical Center

Verification Date

November 2005

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP